phase 3 clinical trials

Exclusive: Centre Approved Corbevax for 12-14 Year Olds Without NTAGI Clearance

DCGI Okays Covaxin For Young Adults Aged 12-18 Years, With Some Conditions

Covaxin Is 50% Effective, New Study Says. What Does That Mean Exactly?

Bharat Biotech’s Covaxin Phase 3 Trial Paper Published, Finally

Everything You Need To Know About Molnupiravir, Merck’s New High-hope COVID Drug

Serum Institute Seeks DCGI Nod for COVID Vaccine ‘Covovax’

Biological E Hopes To Roll Out COVID-19 Vaccine ‘Corbevax’ by Late November